弗吉尼亞南方國家銀行 SONA 深 滬
等待開盤 07-21 09:30:00 美东时间
15.09
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 15.09
- 總市值 3.69亿
- 52周最高 14.62
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.58
- 委 比 0.00%
- 總股本 2443.85万
- 歷史最高 15.52
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.16
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sona BLW Precision Forgings Ltd. (SONACOMS) Gets a Hold from J.P. Morgan
J.P. Morgan analyst Amyn Pirani maintained a Hold rating on Sona BLW Precision ...
04-17 22:26
Sonata Software Projects Lower Q4 Revenue from Key Client
Sonata Software Limited ( ($IN:SONATSOFTW) ) has issued an announcement. Sonata...
04-17 08:33
Sona BLW Announces Trading Window Closure in Compliance with SEBI Regulations
The latest update is out from Sona BLW Precision Forgings Ltd. ( ($IN:SONACOMS)...
03-17 14:44
Sonata Software Limited Announces Approval of Employee Trading Plan
Sonata Software Limited ( ($IN:SONATSOFTW) ) just unveiled an announcement. Son...
03-15 08:32
中核五公司承建！我国出海北非最大LNG项目升顶成功
阿尔及利亚，斯基克达当地时间2月25日上午11点30分，由中石化广州/洛阳工程有限公司总承包，中核集团旗下中国核建重要成员单位中核五公司承建的阿尔及利亚国家石油...
02-25 20:28
Sinopec Publica El Primer Informe Sobre Desarrollo Sostenible En Argelia
ALGIERS, Argelia, 31 de diciembre de 2024 /PRNewswire/ -- China Petroleum &...
2024-12-31 19:06
FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)
https://www.fda.gov/media/161640/download WARNING: HEMATOLOGIC MALIGNANCY Hematologic malignancy, including life-threatening cases of myelodysplastic syndrome, has occurred in patients treated with SKYSONA. Patients
2024-11-28 00:35
Sona Nanotech Secures Patent and Strengthens Leadership
Sona Nanotech Inc (TSE:SONA) has released an update. Sona Nanotech Inc. has sec...
2024-10-22 05:08
捷报！杰瑞油气工程斩获巴林国家石油公司天然气工程项目
9月25日，杰瑞集团全资子公司杰瑞石油天然气工程有限公司与巴林国家石油公司BAPCO签署了7个天然气增压站工程总承包项目，合同含税总金额达3.16亿美元（约合...
2024-09-25 18:59
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The initiative includes a 25% workforce reduction and focuses on advancing key gene therapy launches like LYFGENIA, ZYNTEGLO, and SKYSONA.
2024-09-25 00:14
